A comparison of 25 mg and 50 mg oestradiol implants in the control of climacteric symptoms following hysterectomy and bilateral salpingo-oophorectomy

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 107, Issue 8, 2000, Pages 1012-1016

  Panay, N ^a   Versi, E ^b   Savvas, M ^a  

^a UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN;

ADULT; ARTICLE; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FOLLITROPIN BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYSTERECTOMY; IMPLANT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALPINGOOOPHORECTOMY;

CLIMACTERIC; DOUBLE-BLIND METHOD; DRUG IMPLANTS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYSTERECTOMY; MIDDLE AGED; OVARIECTOMY;

EID: 0033944065     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2000.tb10405.x     Document Type: Article

References (20)

1. Chakravarti S, Collins WP, Newton JR, Oram DH, Studd JWW. Endocrine changes and symptomatology after oophorectomy in pre-menopausal women. Br J Obstet Gynaecol 1977; 84: 769–775.
2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47–63.
3. Ettinger B, Genant HK, Cann CE. Long term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102:319–324.
4. Greenblatt RB, Suran RR. Indications for hormone pellets in the therapy of endocrine and gynecological disorders. Am J Obstet Gynecol 1949; 47: 294–301.
5. Brincat M, Magos AL, Studd JWW. Subcutaneous hormone implants for the control of climacteric symptoms. Lancer 1984; 1: 16–18.
6. Studd JWW, Savvas M, Watson NR, Garnett T, Cooper D. Substantial increase in bone density with subcutaneous oestradiol and testosterone implants. Am J Obstet Gynecol 1990; 163:1474–1495.
7. Studd JWW, Collins WP, Chakravarti S, Newton JR, Oram D, Parsons A. Oestradiol and testosterone implants in the treatment of psychosexual problems in the postmenopausal woman. Br J Obstet Gynaecol. 1977; 84: 314–315.
8. Burger H, Hailes J, Nelson J, Menelaus M. Effect of combined implants of estradiol and testosterone on libido in postmenopausal women. BMJ 1984; 294: 936–937.
9. Ferguson KJ, Hoegh C, Johnson S. Estrogen replacement therapy: a survey of women's knowledge and attitudes. Arch Int Med 1989; 149: 133.
10. Studd JWW. Complications of hormone replacement therapy in postmenopausal women. J R Soc Med 1992; 85: 376–378.
11. Barlow DH, Grosset KA, Hart H, Hart DM. A study of the experience of Glasgow women in the climacteric years. Br J Obstet Gynaecol 1989; 96: 1192–1197.
12. Cheung AP, Wren BG. A cost-effectiveness analysis of hormone replacement therapy. Med J Aus 1992; 56: 312–316.
13. Owen EJ, Siddle NC, McGarrigle HT, Pugh MA. 25 mg oestradiol implants: the dosage of first choice for subcutaneous oestrogen replacement therapy Br J Obstet Gynaecol 1992; 99: 671–675.
14. Holland EF, Leather AT, Studd JWW. The effect of 25 mg percutaneous oestradiol implants on the bone mass of postmenopausal women. Obstet Gynecol 1994; 83: 43–6.
15. Thom MH, Collins WP, Studd JWW. Hormone profiles in postmenopausal women after therapy with subcutaneous implants. Br J Obstet Gynaecol 1981; 88: 426–433.
16. Savvas M, Studd JWW, Fogelman I, Dooley M, Montgomery J, Murby B. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in post-menopausal women. BMJ 1988; 297: 331–333.
17. Studd JWW, Holland EFN, Leather AT, Smith RNJ. The dose response of percutaneous oestradiol implants on the skeletons of postmenopausal women. Br J Obstet Gynaecol 1994; 101: 787–791.
18. Notelovitz M, Johnston M, Smith S, Kitchens C. Metabolic and hormonal effects of 25 mg and 50 mg 17 beta estradiol implants in surgically menopausal women. Obstet Gynecol 1987; 70: 749–754.
19. Gangar K, Cust M, Whitehead MI. Symptoms of oestrogen deficiency associated with supraphysiological plasma oestradiol levels in women with oestradiol implants. BMJ 1989; 299: 601–602.
20. Garnett T, Studd JWW, Henderson A, Watson NR, Savvas M, Leather A. Hormone implants and tachyphylaxis. Br J Obstet Gynaecol 1990; 97: 917–921.